Biogen looks to Apellis acquisition to boost lagging Leqembi sales
read at Endpoints ↗DealNeutral
Biogen CEO Chris Viehbacher said the company's Alzheimer's drug Leqembi has underperformed since its 2023 launch.
The drug, co-developed with Eisai, has struggled to meet sales expectations, prompting the firm to seek additional revenue sources.
Biogen recently completed a deal to acquire assets from Apellis, adding several late-stage candidates to its pipeline.
The company expects the Apellis portfolio to help offset Leqembi's weak sales and sustain growth through 2027.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Biogen counts on drugs from Apellis deal to patch Leqembi's slow sales”
read at Endpoints ↗94 words · retrieved Jul 23
comments(0)
5-min edit window · permanent after that